Immuron Limited American Depositary Shares
IMRN
IMRN: Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
moreShow IMRN Financials
Recent trades of IMRN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMRN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions for the treatment and/or prophylaxis of Dec. 04, 2018
-
Patent Title: Anti-lps enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder Nov. 06, 2018
-
Patent Title: Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder Apr. 17, 2018
-
Patent Title: Composition and method for the treatment and prevention of enteric bacterial infections Aug. 02, 2016
-
Patent Title: Composition and method for the treatment and prevention of enteric bacterial infections Jan. 28, 2014
Federal grants, loans, and purchases
Followers on IMRN's company Twitter account
Number of mentions of IMRN in WallStreetBets Daily Discussion
Recent insights relating to IMRN
Recent picks made for IMRN stock on CNBC
ETFs with the largest estimated holdings in IMRN
Flights by private jets registered to IMRN